RecruitingPhase 2NCT06004661
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Studying MiT family translocation renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- AAA617(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18-100 years · MALE
- Timeline
- 2024 – 2026
Study locations (9)
- Mount Sinai Hosp Med School, New York, New York, United States
- Novartis Investigative Site, Paris, France
- Novartis Investigative Site, Vandœuvre-lès-Nancy, France
- Novartis Investigative Site, Essen, Germany
- Novartis Investigative Site, München, Germany
- Novartis Investigative Site, Milan, Italy
- Novartis Investigative Site, Naples, Italy
- Novartis Investigative Site, Granada, Andalusia, Spain
- Novartis Investigative Site, El Palmar, Murcia, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06004661 on ClinicalTrials.govOther trials for MiT family translocation renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07571551Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell CarcinomaJinling Hospital, China
- RECRUITINGNANCT07073703Effectiveness of a Personalized 6-month Programme on Frailty in Older Patients Treated for Bladder or Kidney Cancer.Centre Hospitalier Universitaire de Saint Etienne
- RECRUITINGNANCT06138067Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer PatientsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGPHASE1NCT06966024Study of DCC-2812 in Participants With Advanced Genitourinary CancersDeciphera Pharmaceuticals, LLC
- RECRUITINGPHASE2NCT07087860Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder CancersMayo Clinic
- RECRUITINGPHASE2NCT07018622Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy ToxicityInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- ACTIVE NOT RECRUITINGNCT06917560Serological Autoantibodies in Early Kidney Cancer Diagnosis and Prognosis: A Multicenter StudyFirst Affiliated Hospital of Fujian Medical University
- ACTIVE NOT RECRUITINGPHASE1NCT06764771A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant TumorsBristol-Myers Squibb
See all trials for MiT family translocation renal cell carcinoma →